Medicus Pharma Ltd

Medicus Pharma’s SkinJect patch shows an 80% response rate for basal cell carcinoma and FDA‑approved prostate trials, yet quarterly losses triple as R&D ramps up – a mixed outlook for investors.

Medicus Pharma, a clinical‑stage biotech investor, joins the Roth Conference to spotlight its FDA‑trial strategy and growth plans amid volatile Nasdaq trading.